Covance has opened a new drug development center in Shanghai, China, aimed at enhancing efficiency and capacity for biotech and pharmaceutical companies. With over 20 years of local experience, Covance offers integrated clinical development solutions and support for both early and late-phase clinical trials, and has demonstrated success in regulatory compliance. Their expanded end-to-end services include biometrics, clinical monitoring, and post-marketing strategies, enabling clients to navigate trials in China and globally.

1. Meet your needs for greater efficiency, expanded capacity
and customized support at the newly opened Covance Drug
Development Center in Shanghai, China
ADVANCE YOUR PROGRAM IN
CHINA WITH FULLY INTEGRATED
CLINICAL DEVELOPMENT SOLUTIONS
Advancing clinical development research and navigating evolving regulations in China is more efficient
with an experienced, in-country partner. As one of the leading contract research organization in China
with 20+ years of in-country experience, we know how to help biotech and pharmaceutical companies to
reach market approval – both in China and around the world. Rely on our skilled teams to:
▶ Support early and late phase, multi-regional clinical trials (MRCT)
▶ Advance global development programs for international, regional, and China-based biotech companies
▶ Navigate drug registration trials in China with global quality standards
Now, with rapidly growing demand for capacity and expertise in China, we’ve expanded and co-located
our services in a new facility in ZhangJiang High Tech Park in Shanghai, China: the Aland Center. By
increasing our support for bioanalytical, central laboratory and clinical development solutions, the Aland
Center efficiently meets your trial’s needs and makes a difference in your development program
Expanded, End-to-End Drug Development Solutions
Rely on our end-to-end solutions that deliver high-quality data to satisfy both the National Medical
Products Administration (NMPA) and meet global regulatory requirements. As a contract research
organization Covance generates more safety and efficacy drug development data than any other company
in the world. From early development to commercialization, our cross-functional teams supports:
Nonclinical safety assessment | Bioanalytical services | Central laboratory capabilities | Specialty testing
laboratories | Clinical development services | Functional Service Provider (FSPx)
Expanded, End-to-End Drug Development Solutions
Optimize your clinical development outcomes with our proven solutions tailored to both local and global
studies.
▶ Clinical Monitoring and Site Management
▶ Project Management
▶ Feasibility & Start-up
▶ Biometrics (DM, Stats Programming, Biostats)
& Drug Safety Services
▶ Medical Monitoring
▶ Pharmacovigilance
▶ Regulatory Consultation/Submissions
▶ Vendor Management & Clinical Ancillary Services

2. Learn more about our drug development solutions at www.covance.com
Covance Inc., headquartered in Princeton, NJ, USA, is the drug development business of Laboratory
Corporation of America Holdings (LabCorp). COVANCE is a registered trademark and the
marketing name for Covance Inc. and its subsidiaries around the world.
The Americas +1.888.COVANCE (+1.888.268.2623) +1.609.452.4440
Europe/Africa +00.800.2682.2682 +44.1423.500888
Asia Pacific +800.6568.3000 +65.6.5686588
© Copyright 2019 Covance Inc. SSCDS096-0719
Count on Our Therapeutic Area Experience to Complement
Your Team’s Expertise
Building on previous knowledge and lessons learned from our studies in China and the
Asia Pacific region, we know how to optimize your strategies and efficiently advance your trials.
*“Other” category includes: Endocrinology, Health control, Immunology, Pain, Psychiatry, Bone & Joint Disease, Ophthalmology,
Dermatology, Autoimmune disease, Urology, Women’s Healthcare
Our Impact in China - and Impressive Results
Covering Your Post-Approval Needs
In 2018, Covance acquired Sciformix to complement and strengthen our post-approval solutions for drug and device
development, safety and adjudication. Working together, we offer:
▶ Post-marketing pharmacovigilance
▶ Regulatory strategies
▶ Market access solutions
Confidently Incorporate China into Your Global Clinical Trial Program
At any phase in your project, you can advance your studies in China, Asia Pacific and beyond with our integrated and
collaborative teams at the Aland Center. Contact your Covance business development representative for more information
about supporting your clinical development at the Aland Center.
In the past five years, Covance has been involved with:
139 studies
1,800+ sites
23,000 patients
Covance achieved:
96% First Patient In (FPI) on Time
97% Recruitment Completion on Time
100% Database Lock on Time
100% No authenticity issues identified by NMPA inspections
2018 and 2017 Asia Pacific CRO Customer Value
Leadership Awards given to Covance from Frost & Sullivan
Oncology/Hematology
49, 35%
CardioMetabolic
24, 17%
Other
23, 17%
Neuroscience
14, 10%
Pulmonary/
Repsiratory,
11, 8%
Infectious
Disease,
11, 8%
Gastroenterology,
7, 5%